Prophylactic treatment with low-molecular-weight heparin and fondaparinux showed a consistent 50% reduction in venous thromboembolism events in acutely ill medical patients.
Effect estimate: 50% reduction
Given the increased number of patients hospitalized for acute medical illnesses and the associated risk of venous thromboembolism (VTE), the use of prophylaxis has become a public health matter. Thromboprophylaxis is not widely practiced in acutely ill medical patients, due in part to the heterogeneity of this group and the perceived difficulty in assessing those who would most benefit from treatment. Nevertheless, the results of recent well-conducted clinical trials support the evidence-based recommendations for more widespread systematic use of low-dose low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) in this population. Three large well-controlled studies (MEDENOX, PREVENT, and ARTEMIS) in acutely ill medical patients confirm previous findings that different at-risk patient populations show a consistent 50% reduction in VTE events with LMWH and fondaparinux. A meta-analysis in nearly 5000 patients in internal medicine comparing UFH and LMWH revealed a trend for reduction of deep vein thrombosis and pulmonary embolism with LMWH. Based on duration of use in clinical trials in acutely ill medical patients, prophylactic treatment with UFH and LMWH is recommended for 2 weeks.
Leizorovicz et al. (Tue,) conducted a review in Venous thromboembolism. Low-molecular-weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux was evaluated on Venous thromboembolism (VTE) events (50% reduction). Prophylactic treatment with low-molecular-weight heparin and fondaparinux showed a consistent 50% reduction in venous thromboembolism events in acutely ill medical patients.